Improving systemic therapy selection for inflammatory skin diseases: A clinical need survey

Empirical decisions to select therapies for psoriasis (PSO) and atopic dermatitis (AD) can lead to delays in disease control and increased health care costs. However, routine molecular testing for AD and PSO are lacking. To examine (1) how clinicians choose systemic therapies for patients with PSO a...

Full description

Saved in:
Bibliographic Details
Published in:JAAD international 2024-09, Vol.16, p.49-56
Main Authors: Brownstone, Nicholas D., Farberg, Aaron S., Litchman, Graham H., Quick, Ann P., Siegel, Jennifer J., Hurton, Lenka V., Goldberg, Matthew S., Lio, Peter A.
Format: Article
Language:English
Subjects:
atopic dermatitis
biologics
gene expression profile test
inflammatory skin disease
molecular
Original
precision medicine
psoriasis
response to therapy
systemic therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Empirical decisions to select therapies for psoriasis (PSO) and atopic dermatitis (AD) can lead to delays in disease control and increased health care costs. However, routine molecular testing for AD and PSO are lacking. To examine (1) how clinicians choose systemic therapies for patients with PSO and AD without molecular testing and (2) to determine how often the current approach leads to patients switching medications. A 20-question survey designed to assess clinician strategies for systemic treatment of AD and PSO was made available to attendees of a national dermatology conference in 2022. Clinicians participating in the survey (265/414, 64% response rate) ranked “reported efficacy” as the most important factor governing treatment choice (P 
ISSN:2666-3287
2666-3287
DOI:10.1016/j.jdin.2024.03.019